Eli Lilly said worldwide revenue in Q2 2025 was $15.56 billion, an increase of 38% compared with Q2 2024, driven by volume growth of 42%, partially offset by a 6% decrease due to lower realized prices.

1. 01

   Eli Lilly said worldwide revenue in Q2 2025 was $15.56 billion, an increase of 38% compared with Q2 2024, driven by volume growth of 42%, partially offset by a 6% decrease due to lower realized prices.

2. 02

   The company said Mounjaro revenue in Q2 2025 increased 68% to $5.20 billion, and U.S. Zepbound revenue increased 172% to $3.38 billion.

3. 03

   Eli Lilly said net income in Q2 2025 was $5.66 billion ($6.29 per share) compared with $2.97 billion ($3.28 per share) in Q2 2024. Both quarters included acquired IPR&D charges of $0.14 per share.

4. 04

   The company raised its full-year 2025 revenue guidance from the prior range of $58.0 billion to $61.0 billion to $60.0 billion to $62.0 billion, and said reported EPS guidance is in the range of $20.85 to $22.10.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.